DE60117873D1 - Verfahren zur herstellung von submikropartikel-suspensionen pharmazeutischer substanzen - Google Patents

Verfahren zur herstellung von submikropartikel-suspensionen pharmazeutischer substanzen

Info

Publication number
DE60117873D1
DE60117873D1 DE60117873T DE60117873T DE60117873D1 DE 60117873 D1 DE60117873 D1 DE 60117873D1 DE 60117873 T DE60117873 T DE 60117873T DE 60117873 T DE60117873 T DE 60117873T DE 60117873 D1 DE60117873 D1 DE 60117873D1
Authority
DE
Germany
Prior art keywords
submicroparticle
suspensions
producing
pharmaceutical substances
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60117873T
Other languages
English (en)
Other versions
DE60117873T2 (de
Inventor
E Kipp
Chung Wong
J Doty
L Rebbeck
Sean Brynjelsen
Jane Werling
Rajaram Sriram
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter International Inc
Original Assignee
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/874,637 external-priority patent/US6869617B2/en
Priority claimed from US09/953,979 external-priority patent/US6951656B2/en
Priority claimed from US10/035,821 external-priority patent/US6977085B2/en
Priority claimed from US10/021,692 external-priority patent/US6884436B2/en
Application filed by Baxter International Inc filed Critical Baxter International Inc
Application granted granted Critical
Publication of DE60117873D1 publication Critical patent/DE60117873D1/de
Publication of DE60117873T2 publication Critical patent/DE60117873T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
DE60117873T 2000-12-22 2001-12-20 Verfahren zur herstellung von submikropartikel-suspensionen pharmazeutischer substanzen Expired - Lifetime DE60117873T2 (de)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US874637 1986-06-16
US874499 1986-06-16
US21692 1998-02-10
US25816000P 2000-12-22 2000-12-22
US258160P 2000-12-22
US09/874,637 US6869617B2 (en) 2000-12-22 2001-06-05 Microprecipitation method for preparing submicron suspensions
US09/874,499 US7037528B2 (en) 2000-12-22 2001-06-05 Microprecipitation method for preparing submicron suspensions
US874799 2001-06-05
US09/874,799 US6607784B2 (en) 2000-12-22 2001-06-05 Microprecipitation method for preparing submicron suspensions
US953979 2001-09-17
US09/953,979 US6951656B2 (en) 2000-12-22 2001-09-17 Microprecipitation method for preparing submicron suspensions
US10/035,821 US6977085B2 (en) 2000-12-22 2001-10-19 Method for preparing submicron suspensions with polymorph control
US35821 2001-10-19
US10/021,692 US6884436B2 (en) 2000-12-22 2001-12-12 Method for preparing submicron particle suspensions
PCT/US2001/049737 WO2002055059A2 (en) 2000-12-22 2001-12-20 Method for preparing submicron particle suspensions

Publications (2)

Publication Number Publication Date
DE60117873D1 true DE60117873D1 (de) 2006-05-04
DE60117873T2 DE60117873T2 (de) 2006-08-24

Family

ID=27567644

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60117873T Expired - Lifetime DE60117873T2 (de) 2000-12-22 2001-12-20 Verfahren zur herstellung von submikropartikel-suspensionen pharmazeutischer substanzen

Country Status (16)

Country Link
EP (2) EP1347747B1 (de)
JP (1) JP4376518B2 (de)
CN (1) CN100512798C (de)
AT (1) ATE319432T1 (de)
AU (2) AU2002249836B2 (de)
BR (1) BR0116377A (de)
CA (1) CA2431705C (de)
DE (1) DE60117873T2 (de)
DK (1) DK1347747T3 (de)
ES (1) ES2260337T3 (de)
HU (1) HUP0501030A3 (de)
IL (1) IL156310A0 (de)
MX (1) MXPA03005496A (de)
NO (1) NO20032860L (de)
NZ (1) NZ526608A (de)
WO (1) WO2002055059A2 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8067032B2 (en) * 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
EP1429749A2 (de) 2001-09-26 2004-06-23 Baxter International Inc. Herstellung von nanopartikeln im submikrometerbereich durch dispersion und entzug des lösungsmittels oder der flüssigen phase
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
GB0216700D0 (en) 2002-07-18 2002-08-28 Astrazeneca Ab Process
US20040028747A1 (en) * 2002-08-06 2004-02-12 Tucker Christopher J. Crystalline drug particles prepared using a controlled precipitation process
GB0302673D0 (en) 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
US7511079B2 (en) * 2003-03-24 2009-03-31 Baxter International Inc. Methods and apparatuses for the comminution and stabilization of small particles
EP1617818A1 (de) * 2003-04-29 2006-01-25 Baxter International Inc. Formulierung, um ein antimikrobielles arzneimittel gegen organismen wirksam zu machen, die normalerweise als resistent dagegen gelten
BRPI0414970A2 (pt) 2003-06-24 2012-12-11 Baxter Int método para transporte de drogas ao cérebro
US8986736B2 (en) 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
SG135204A1 (en) * 2003-07-18 2007-09-28 Baxter Int Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation
JPWO2005013938A1 (ja) * 2003-08-06 2006-09-28 エーザイ株式会社 薬物超微粒子の製造法及び製造装置
GB0327390D0 (en) * 2003-11-25 2003-12-31 Pfizer Ltd Pharmaceutical formulations
WO2005055983A2 (en) * 2003-12-09 2005-06-23 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
AU2005209243A1 (en) * 2004-01-29 2005-08-11 Baxter Healthcare S.A. Nanosuspensions of anti-retroviral agents for increased central nervous system delivery
DK1731138T3 (en) * 2004-03-31 2016-06-06 Toyama Chemical Co Ltd Fine dispersion of sparingly soluble drug and the process for preparing the
CN101310011A (zh) 2004-06-15 2008-11-19 巴克斯特国际公司 固相微颗粒治疗剂的离体应用
DE102004031538A1 (de) * 2004-06-29 2006-02-09 Baxter International Inc., Deerfield Pharmazeutische Darreichungsform zur oralen Verabreichung eines schwerlöslichen Wirkstoffs, Verfahren zu deren Herstellung und Kit
WO2006066063A1 (en) * 2004-12-15 2006-06-22 Elan Pharma International Ltd. Nanoparticulate tacrolimus formulations
AU2006227623B2 (en) * 2005-03-17 2011-10-20 Elan Pharma International Limited Injectable compositions of nanoparticulate immunosuppressive compounds
DE102005053862A1 (de) * 2005-11-04 2007-05-10 Pharmasol Gmbh Verfahren und Vorrichtung zur Herstellung hochfeiner Partikel sowie zur Beschichtung solcher Partikel
JP2009516003A (ja) * 2005-11-15 2009-04-16 バクスター・インターナショナル・インコーポレイテッド リポキシゲナーゼ阻害剤の組成物
EP2259798B1 (de) 2008-03-05 2013-12-11 Baxter International Inc. Zusammensetzungen und verfahren zur wirkstofffreisetzung
DE102009008478A1 (de) 2009-02-11 2010-08-19 PHAST Gesellschaft für pharmazeutische Qualitätsstandards mbH Vorrichtung und Verfahren zur Herstellung pharmazeutisch hochfeiner Partikel sowie zur Beschichtung solcher Partikel in Mikroreaktoren
US10952965B2 (en) 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
BR112012023983B1 (pt) 2010-03-22 2019-03-26 Instillo Gmbh Método e dispositivo para fabricação de micro ou nanopartículas
CN102384973B (zh) * 2011-08-10 2014-09-10 华南理工大学 快速定量检测羟甲基糠醛的免疫层析试纸条及其制备方法
CN102268103B (zh) * 2011-09-02 2013-06-05 中国海洋大学 一种壳聚糖醋酸盐的制备方法
US9248139B2 (en) * 2011-12-21 2016-02-02 Bristol-Myers Squibb Company Co-processing method and formulations for HIV attachment inhibitor prodrug compound and excipients
CN103212079A (zh) * 2013-04-26 2013-07-24 陆媛 一种预防和/或治疗感冒的含服药物组合物及其应用
CN104905262B (zh) * 2015-05-29 2017-12-22 湖北省农业科学院农产品加工与核农技术研究所 一种制备虫草灵芝复合制剂的方法
KR101725508B1 (ko) * 2015-07-31 2017-04-11 국방과학연구소 헥사나이트로스틸벤 입자의 제조 방법과 그 장치
CN105969316B (zh) * 2016-06-03 2020-11-10 宁海德宝立新材料有限公司 一种用于热敷的相变储热复合材料
CA3030308C (en) 2016-07-29 2022-04-05 The Board Of Trustees Of Western Michigan University Magnetic nanoparticle-based gyroscopic sensor
CN108031142A (zh) * 2017-12-13 2018-05-15 上海合全药物研发有限公司 一种简化的利用湿磨来制备大量微晶种的装置及方法
CN115349630A (zh) * 2022-06-20 2022-11-18 海宁凤鸣叶绿素有限公司 水分散性叶黄素微囊粉的制备方法
WO2024136660A1 (en) * 2022-12-22 2024-06-27 Nanomi B.V. Process for preparing stable nanoparticle and composition thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1282405C (en) * 1984-05-21 1991-04-02 Michael R. Violante Method for making uniformly sized particles from water-insoluble organic compounds
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4606940A (en) * 1984-12-21 1986-08-19 The Ohio State University Research Foundation Small particle formation and encapsulation
FR2634397B2 (fr) * 1986-12-31 1991-04-19 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules
FR2608988B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
IL86211A (en) * 1987-05-04 1992-03-29 Ciba Geigy Ag Oral forms of administration for carbamazepine in the forms of stable aqueous suspension with delayed release and their preparation
CA2044706C (en) * 1990-06-15 2003-02-25 Michael Midler Jr. Crystallization method to improve crystal structure and size
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
GB9413202D0 (en) * 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
SE9403846D0 (sv) * 1994-11-09 1994-11-09 Univ Ohio State Res Found Small particle formation
KR19990001564A (ko) * 1997-06-16 1999-01-15 유충식 용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제
FI973804A (fi) * 1997-09-26 1999-03-27 Orion Yhtymae Oy Levosimendaanin oraalisia koostumuksia
AU1511399A (en) * 1997-12-31 1999-07-19 Choongwae Pharma Corporation Method and composition of an oral preparation of itraconazole
EP1079808B1 (de) * 1998-05-29 2004-02-11 Skyepharma Canada Inc. Gegen hitzeeinwirkung geschützte mikropartikel und verfahren zur terminalen dampfsterilisation derselben
KR100549095B1 (ko) * 1998-07-17 2006-02-06 얀센 파마슈티카 엔.브이. 항진균제 및 중합체로 코팅된 코어를 갖는 펠릿
ATE307808T1 (de) * 1999-03-24 2005-11-15 Scherer Technologies Inc R P Pharmazeutische formulierungen mit verbesserter löslichkeit in wasser
KR100331529B1 (ko) * 1999-06-16 2002-04-06 민경윤 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법

Also Published As

Publication number Publication date
AU2006201943A1 (en) 2006-06-01
DE60117873T2 (de) 2006-08-24
NO20032860L (no) 2003-08-21
CA2431705A1 (en) 2002-07-18
ES2260337T3 (es) 2006-11-01
AU2002249836B2 (en) 2006-12-14
JP2004538249A (ja) 2004-12-24
EP1642571A2 (de) 2006-04-05
NZ526608A (en) 2006-06-30
CN100512798C (zh) 2009-07-15
EP1347747B1 (de) 2006-03-08
CN1505503A (zh) 2004-06-16
DK1347747T3 (da) 2006-04-10
EP1347747A2 (de) 2003-10-01
HUP0501030A3 (en) 2008-04-28
MXPA03005496A (es) 2004-05-14
BR0116377A (pt) 2005-12-13
WO2002055059A3 (en) 2002-09-06
EP1642571A3 (de) 2007-06-27
JP4376518B2 (ja) 2009-12-02
HUP0501030A2 (en) 2007-02-28
WO2002055059A2 (en) 2002-07-18
ATE319432T1 (de) 2006-03-15
CA2431705C (en) 2010-10-05
IL156310A0 (en) 2004-01-04
NO20032860D0 (no) 2003-06-20

Similar Documents

Publication Publication Date Title
ATE319432T1 (de) Verfahren zur herstellung von submikropartikel- suspensionen pharmazeutischer substanzen
DE60222734D1 (de) Mikropartikel und Verfahren zur deren Herstellung
DE60009326D1 (de) Verfahren zur herstellung von silicoaluminophosphat-molekularsieben
DE69002905D1 (de) Verfahren zur Herstellung von lipidischen Mikropartikeln.
ATE353081T1 (de) Verfahren zur herstellung von duloxetin und deren verwendeten zwischenprodukten
DE69919599D1 (de) Verfahren zur herstellung von 4-trifluormethylsulfinylpyrazolderivat
ATE256458T1 (de) Verfahren zur mikroverkapselung von wasserlöslichen substanzen
DE60135296D1 (de) Verbessertes Verfahren und Methode zur Herstellung von asymmetrischen monofunktionalisierten Indocyaninmarkern sowie erhaltene Verbindungen
DE3862604D1 (de) Verfahren zur herstellung von konzentrierten, waessrigen farbstoffzubereitungen wasserloeslicher organischer farbstoffe.
DE60227630D1 (de) Verfahren zur Herstellung von Fullerene
ATE299858T1 (de) Verfahren zur herstellung von diaminodiphenylmethan und seiner höheren homologen
ATE298747T1 (de) Verfahren zur herstellung von 5- hydroxybenzo(b)thiophen-3-carbonsäure
ATE440846T1 (de) Verfahren zur herstellung von chloriden von phthalocyaninderivaten, die wenigstens eine quaternäre ammoniumgruppe enthalten
ATE275149T1 (de) Verfahren zur herstellung von taxanderivaten
ATE317259T1 (de) Verfahren zur herstellung fester formulierungen von natrium-3-hydroxy-3-methylbutyrat
YU59401A (sh) Postupak za proizvodnju alendronske kiseline
ATE384067T1 (de) Verfahren zur herstellung von 3-cephemderivaten
DE69618496D1 (de) Verfahren zur Derivatisierung von Polyglukosaminen
DE60004850D1 (de) Verfahren zur herstellung von (r) und (s)-aminocarnitin und deren derivative aus d- und l-aspargin säure
ATE285393T1 (de) Verfahren zur herstellung von (r)-2-brom-3- phenylpropionsäure
ATE301637T1 (de) Verfahren zur herstellung von n-geschützten azetidin-2-carbonsäuren
ATE360086T1 (de) Verfahren zur herstellung von avermectinderivaten
ATE171937T1 (de) Verfahren zur herstellung von diazomethanderivaten
DE60031315D1 (de) Verfahren zur Herstellung von Derivaten von i(1,5-Diaryl)pyrazol-3-ylöpropansäure
ATE325174T1 (de) Verfahren zur herstellung von photolumineszenten polarisatoren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition